ARTICLE | Company News
EpiTherapeutics, Gilead deal
May 11, 2015 7:00 AM UTC
Gilead acquired epigenetics company EpiTherapeutics for $65 million in cash. EpiTherapeutics is developing preclinical small molecule inhibitors of histone demethylases to treat cancer. ...